Quantitative Chiral Separations on KRAS Inhibitor Sotorasib by UHPLC-MS/MS: Method Validation and Enantioselective Pharmacokinetics Assessment in Rat Plasma.
Sign Up to like & getrecommendations! Published in 2025 at "Chirality"
DOI: 10.1002/chir.70037
Abstract: In this research, estimation of enantioselective pharmacokinetics and biological interconversion of sotorasib were investigated. This is the first report for the novel chiral liquid chromatography-tandem mass spectrometry method for the enantioselective pharmacokinetics determination in biological… read more here.
Keywords: method; method validation; sotorasib; quantitative chiral ... See more keywords
Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation
Sign Up to like & getrecommendations! Published in 2025 at "Advances in Therapy"
DOI: 10.1007/s12325-025-03259-8
Abstract: Sotorasib and adagrasib are the only treatments approved in the USA and Europe for advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). In the absence of head-to-head trials, a matching-adjusted indirect comparison (MAIC) was conducted… read more here.
Keywords: non small; cancer; cell lung; sotorasib ... See more keywords
Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of chemotherapy"
DOI: 10.1080/1120009x.2025.2503052
Abstract: Mutations in the KRAS gene are the most common gain-of-function mutations found in lung adenocarcinomas. The most prevalent mutation, KRAS G12C, occurs in 13% of lung adenocarcinomas. Sotorasib is an irreversible small molecule inhibitor that… read more here.
Keywords: combination therapy; lung; sotorasib; kras g12c ... See more keywords
Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2024 at "Future oncology"
DOI: 10.1080/14796694.2024.2430172
Abstract: Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is prognostic of poor survival for patients with non-small cell lung cancer (NSCLC). KRAS G12C mutations occur in 13% of NSCLC cases and despite the frequency of… read more here.
Keywords: non small; lung cancer; cell lung; sotorasib ... See more keywords
Abstract 3871: KRAS G12C mutant allele amplification drives resistance to sotorasib in vitro
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3871
Abstract: Sotorasib is an approved KRASG12C-selective inhibitor for the treatment of KRAS p.G12C-mutant advanced and previously treated non-small cell lung cancers (NSCLC). Acquired resistance due to genomic alterations following sotorasib treatment has been observed in 28%… read more here.
Keywords: kras g12c; amplification; resistance; mutant allele ... See more keywords
Abstract 370: Resistance to sotorasib does not confer resistance to adagrasib: Why?
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-370
Abstract: KRAS mutations are among the most common gain-of-function alterations, found in approximately 30% of lung adenocarcinomas. These mutations primarily occur at codon 12, leading to amino acid substitutions that impair KRAS's intrinsic GTPase activity, rendering… read more here.
Keywords: resistance; resistance sotorasib; sotorasib; sotorasib confer ... See more keywords
Abstract 5517: Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-5517
Abstract: Acquired resistance (AR) to sotorasib, an FDA-approved KRAS inhibitor, poses a significant challenge in treating KRASG12C mutant NSCLC. Despite initial responses, patients invariably develop resistance, necessitating alternative therapeutic strategies. The mechanisms of AR include the… read more here.
Keywords: resistance; therapy; mutant nsclc; sotorasib ... See more keywords
Abstract B015: Wildtype RAS activity and PI3K signaling as new vulnerabilities in cells with acquired resistance to sotorasib
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-b015
Abstract: Purpose: Sotorasib (AMG510) has demonstrated remarkable response in lung cancer patients with tumors driven by oncogenic KRASG12C mutation. However, recently published clinical data identified acquired mutations in RAS and other genomic alterations as potential mechanisms… read more here.
Keywords: ras activity; lu65 amgr; resistance; pi3k signaling ... See more keywords
Sotorasib Edges Closer to Approval.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2021-0309
Abstract: The KRASG12C inhibitor sotorasib continues to impress in non-small cell lung cancer: In the phase II CodeBreak 100 trial, the agent elicited responses in more than a third of patients and led to a median… read more here.
Keywords: closer approval; approval; edges closer; sotorasib ... See more keywords
Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.9003
Abstract: 9003Background: In the registrational phase 2 CodeBreaK 100 trial, sotorasib demonstrated an objective response rate (ORR) of 37.1% (95% Cl: 28.6, 46.2) and a median progression-free survival (PFS)... read more here.
Keywords: sotorasib; codebreak 100; 100 trial; phase codebreak ... See more keywords
Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the US.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e20567
Abstract: e20567 Background: Sotorasib was used for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with KRASG12Cmutation who had received at least one systematic therapy, showing good antitumor activity and… read more here.
Keywords: non small; lung cancer; cell lung; small cell ... See more keywords